In November 2025, ICH endorsed M11, the first internationally harmonized clinical trial protocol template. The FDA finalized guidance in May 2026, and the EMA adopted it in December 2025. But M11 only defines what protocol content should contain, not how software systems can actually use it. That's where CDISC's Unified Study Definitions Model (USDM) comes in. USDM turns M11's structured content into a machine-readable data model that EDC systems, CTMS platforms, and registry submissions can consume directly.
Right now, roughly 90% of protocols still exist only as unstructured text, according to TransCelerate. That means every downstream system gets built by someone reading the protocol document and re-entering content by hand. The average lag between protocol approval and study start is four months, largely due to this manual work. When amendments happen, and 57% of trials have at least one substantial amendment, the cycle repeats. A 2016 Tufts analysis found the median direct cost of a Phase III amendment was over half a million dollars, not counting delayed enrollment.
For sites, USDM won't eliminate amendments or complexity. But once your sponsor's systems integrate with it, protocol changes should cascade automatically to your EDC, informed consent forms, and training materials instead of requiring fresh manual updates every time.